Academic-Community Collaboration and Future Directions for Bispecific Therapy

Dr. Nooka emphasizes that complex treatment decisions involving CAR-T versus bispecific antibodies versus other therapies must occur in academic centers, despite his profound respect for community physicians. These discussions require comprehensive treatment sequencing to avoid "cannibalizing" future therapeutic options, as choosing one treatment creates a domino effect affecting subsequent choices. Academic-community collaboration has demonstrated improved patient survival in large trials, with patients receiving treatment locally after initial academic consultation for strategic planning.

Community physicians face unique challenges managing 20-25 patients daily across 30+ different cancer types, making specialized knowledge of each disease area practically impossible. When patients develop serious complications like CRS requiring hospitalization, time constraints limit community physicians' ability to manage these events. Academic centers can provide initial bispecific administration during the first month, followed by community-based maintenance dosing, or larger practices can develop internal expertise for these specialized treatments.

Dr. Nooka draws parallels to daratumumab's development trajectory, which initially showed 30% response rates as a single agent in heavily pretreated patients but demonstrated remarkable combination potential in early relapse settings (Pollux and Castor trials) and eventually moved to frontline quadruplet regimens achieving 60-70% MRD negativity. Bispecific antibodies are following a similar path: teclistamab, elranatamab, and talquetamab achieved 60% response rates after 5 prior therapies, but combination strategies are proving transformative.

The MajesTEC-3 data represents just "the tip of the iceberg," with future combinations including teclistamab with CELMoDs in development. Preliminary frontline data shows remarkable promise. Bispecific-lenalidomide combinations in frail patients achieved nearly 100% MRD negativity, whereas post-transplant consolidation trials demonstrate exceptional MRD-negative rates.

Dr. Nooka predicts bispecific antibodies will transition to newly diagnosed settings within the next few years as combination therapies, with the ultimate goal of achieving MRD negativity for all patients. This advancement holds particular importance for high-risk patients, though standard-risk patients also benefit significantly. The evolution represents a paradigm shift toward deeper, more durable responses across all treatment settings in multiple myeloma.